GSMA Mobile 360 Debuts in Malaysia
The GSMA today announced the first speakers for the 2019 Mobile 360 Series – Digital Societies conference, which will take place 24-26 September at JW Marriott Hotel Kuala Lumpur, Malaysia. The event is supported by the Malaysian Communications and Multimedia Commission (MCMC) and also the Malaysia Convention and Exhibition Bureau (MyCEB). Host sponsor for the event is Axiata with other event sponsors including Fiberhome (Headline Sponsor), Edotco, Gigabyte, Huawei and Telepin (Industry Sponsors), as well as Arm (eSim Supporting Sponsor).
“We are excited to bring the Mobile 360 – Digital Societies event to Malaysia for the first time as mobile technology is no doubt playing a pivotal role in driving economic development in the Asia Pacific Region,” said, John Hoffman, CEO, GSMA Ltd. “This three-day event will provide a perfect platform for stakeholders to share their experiences and expand the positive impact of mobile throughout this vibrant and diverse region.”
Keynote Speakers
At the event, industry-leading speakers will shine a light on APAC innovation examining how developments in these core areas are powering digital transformation across the region. Speakers confirmed to present at Mobile 360 – Digital Societies include:
- Gobind Singh Deo, Minister of Communication and Multimedia, Malaysia
- YBrs. Encik Al-Ishsal Ishak, Chairman, Malaysian Communications and Multimedia Commission
- Sok Puthyvuth, Secretary of State, Cambodia MPTC
- Tony Fernandes, CEO, AirAsia Group
- Dr Hans Wijayasuriya, Corporate EVP and Regional CEO, South Asia, Axiata
- Loke Hwee Wong, VP, APAC, Boku
- Teddy Oetomo, CSO, Bukalapak
- Michael Patent, CEO, Culture Group
- Albern Murty, CEO, Digi Telecommunications
- Suresh Sidhu, CEO, edotco
- Wang Xiaofei, CMO, Fiberhome
- Louise Easterbrook, CFO, GSMA
- Khoo Yuen Hing, CTO, Huawei
- Masayoshi Sakai, Counsellor, Information-technology Promotion Agency, Japan
- Sohee Shin, SVP, Global Business Unit and Global Alliance Division, KT
- Gokhan Ogut, CEO, Maxis Broadband Sdn Bhd
- Maya Arvini, CCO, Qlue
- Takeshi Fukuizumi, Head of Fintech and Blockchain, Softbank
- Foong Yuh Wen, CEO and Founder, Sushivid
- Anthony Socci, President and General Manager, APAC, Synchronoss
- Vince Kadar, CEO, Telepin
- Brad Jones, CEO, Wave Money
- Kaspar Tiri, Co-Founder, Wolf 3D
- David An, CTO, ZTE Group Asia
The full conference agenda is available at https://www.mobile360series.com/digital-societies/agenda/.
In addition to the keynotes, a series of in-depth workshops and sessions will allow a deeper dive into the industry’s most complex challenges looking at topics such as Forging Digital Societies Through Digital Platforms, Building Simple, Clear and Fast Public Services and 5G and Digitalisation. Mobile 360 – Digital Societies will examine the attributes that contribute to a successful digital society. Focusing on the digital platforms enabling new and innovative services, the event highlights the key elements that define a successful digital society including citizenship, commerce, identity, lifestyle and connectivity, and how developments in these key areas can lead to gains for society as a whole.
Women4Tech Leaders Reception
Mobile 360 – Digital Societies will host the first Women4Tech Leaders Reception in APAC on 24 September 2019 from 5:30pm-7:30pm. The event will stimulate discussion on the benefits of encouraging gender diversity in the tech industry and addressing what can be done about the current gender gap through education and public policy. It will also look at ways to promote gender diversity culture in business organisations.
Registration for Women4Tech Leaders Reception is available here: www.mobile360series.com/digital-societies/agenda/apply-to-attend-workshop/#contact
Registration for Mobile 360 – Digital Societies is now open; individuals wishing to attend should visit www.mobile360series.com/digital-societies/attend/attendee-registration/. For further information on Mobile 360 – Digital societies, please visit: www.mobile360series.com/digital-societies/overview/. Further information on the entire Mobile 360 Series of events is available at www.mobile360series.com/. Follow developments and updates on Mobile 360 Series (#mobile360) on Twitter @GSMA and on Facebook www.facebook.com/Mobile360Series.
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005062/en/
Contact information
Media Contacts:
Gearóid Cashman
+44 79 7679 0169
GCashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom